Search

CYT007-TNFQb

CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.

Zebularine

Also shown to inhibit DNA methylation and tumor growth both in vitro and in vivo. … A chemically stable, cytidine analog that displays anti-tumor properties. It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates.

Protein S human

Protein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties [A19561]. It serves as a negative feedback mechanism in the coagulation cascade.

Potassium hydroxide

Potassium hydroxide is also a precursor to other potassium compounds. Potassium hydroxide is used in food to adjust pH, as a stabilizer, and as a thickening agent. … [L1946,L1951] This ingredient has been considered as generally safe as a direct human food ingredient by the FDA, based upon the observance of several good manufacturing practice conditions of use.

Odesivimab

INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.

Vutrisiran

[A249010] Vutrisiran was approved by the FDA in June 2022. … [L34490,L42065] Vutrisiran is commercially available as a conjugate of N-acetylgalactosamine (GalNAc), a residue that enables the delivery of siRNA to hepatocytes.

Clobazam

[A256868] Additionally, clobazam is believed to be a partial agonist to the GABA_A receptor rather than non-selective full receptor agonists like 1,4-benzodiazepines, thus potentially explaining … [A256913] Unlike older 1,4-benzodiazepines, clobazam has a better side-effects profile, particularly less sedative and amnesic effects.

Chromic citrate

Icotinib

. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc

LV-SMENP Vaccine

LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which